6:36 PM
 | 
Sep 10, 2007
 |  BC Extra  |  Top Story

Aspreva, Roche cancel CellCept filing

Aspreva (TSX:ASV; ASPV) and partner Roche (SWX:ROG) said they have decided not to proceed with a regulatory submission for CellCept mycophenolate mofetil to treat lupus nephritis at this time. In June, ASV said a...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >